Although it is a common barrier in cancer immunotherapy, adverse reactions in anti-CD47 immunotherapy are still worth the attention because anemia or other side effects being induced by antibodies or fusion proteins’ binding to erythrocytes or other hemocytes also means less antibodies accumulating in the tumor (43). The gene discussed is CD47; the disease is anemia.